Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2
IMMUNOPRESERVE
Durvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
- NCT03702179 ↗
- Completed
- Spanish Oncology Genito-Urinary Group
- Focused
We haven't built an HCP commentary report on IMMUNOPRESERVE (durvalumab plus tremelimumab plus radiotherapy in localized muscle-invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on IMMUNOPRESERVE so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase II Trial of Durvalumab (Medi4736) Plus Tremelimumab With Concurrent Radiotherapy in Patients With Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Invasive Bladder Cancer
- Interventions
- Durvalumab; Tremelimumab; Radiotherapy
- Arms
- Durvalumab + Tremelimumab · Experimental
- Enrollment
- 32
- Primary outcomes
- Proportion of Patients With Pathological Response
- Sponsor
- Spanish Oncology Genito-Urinary Group with AstraZeneca, MFAR
- Start
- Nov 19, 2018
- Primary completion
- Sep 29, 2020
- Results posted
- Yes
- Registry record
- NCT03702179 · updated Dec 5, 2024